Strategic Partnerships DiaSorin has recently expanded collaborations with Inpeco, McKesson, Thermo Fisher Scientific, and QIAGEN, creating multi-channel distribution and automation opportunities. This presents a pathway to co-sell complementary diagnostics, expand hospital-channel reach, and integrate with automation workflows to drive broader adoption of Liaison NES and VERIGENE panels.

Expanded Point-of-Care FDA CLIA-waived Liaison NES rapid molecular panel received regulatory clearance, enabling exclusive hospital-channel distribution through Thermo Fisher. This signals a growing market for rapid, in-hospital testing and offers upsell potential for adjacent respiratory, flu, RSV, and SARS-CoV-2 panels in urgent-care and ED settings.

Precision Medicine Focus Leadership appointments in precision medicine and companion diagnostics indicate a strategic tilt toward personalized testing. There is an opportunity to bundle molecular panels with companion diagnostic programs, target high-value oncology and immune-related workflows, and partner with hospitals pursuing precision medicine portfolios.

Therapeutic Market Access New antimicrobial and infectious disease assays, including the QuantiFERON-TB Gold Plus II and C. auris Direct kit expansions, open doors for contracts with reference laboratories and regional health systems focusing on TB control, fungal infections, and emerging pathogens—areas where rapid, accurate testing drives patient management and outcomes.

Global Commercial Expansion Recent leadership appointments and international partnerships suggest a push to scale globally with updated go-to-market strategies. Sales teams should target regions enabled by these partnerships, emphasize cross-sell of Simplexa and VERIGENE portfolios, and leverage distribution partners to penetrate mid-to-large hospital networks and reference laboratories.